- Home
- RBOT vs OSRH Comparison
RBOT vs OSRH Comparison
Compare RBOT & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RBOT | OSRH |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 18.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RBOT | OSRH |
|---|---|---|
| Price | $2.13 | $0.59 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 161.6K | ★ 3.0M |
| Earning Date | 03-16-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $0.45 |
| 52 Week High | $16.35 | $11.84 |
Technical Indicators
Market Signals| Indicator | RBOT | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 43.04 |
| Support Level | $2.02 | $0.59 |
| Resistance Level | $2.30 | $0.67 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 12.24 | 14.84 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.